S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
Log in
NASDAQ:SRRK

Scholar Rock Stock Forecast, Price & News

$53.35
-3.45 (-6.07 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$52.69
Now: $53.35
$57.50
50-Day Range
$48.49
MA: $56.01
$64.66
52-Week Range
$9.53
Now: $53.35
$66.72
Volume312,839 shs
Average Volume212,284 shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRK
CUSIPN/A
CIKN/A
Phone857-259-3860
Employees93
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.49 million
Book Value$3.80 per share

Profitability

Net Income$-51,000,000.00
Net Margins-365.84%

Miscellaneous

Market Cap$1.79 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.25 out of 5 stars

Medical Sector

969th out of 1,969 stocks

Biological Products, Except Diagnostic Industry

129th out of 177 stocks

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$53.35
-3.45 (-6.07 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRRK News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions

Is Scholar Rock a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock
or view top-rated stocks.

What stocks does MarketBeat like better than Scholar Rock?

Wall Street analysts have given Scholar Rock a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Scholar Rock wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Scholar Rock
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Saturday, November, 14th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.26. The business had revenue of $3.04 million for the quarter, compared to the consensus estimate of $6.55 million. Scholar Rock had a negative trailing twelve-month return on equity of 80.16% and a negative net margin of 365.84%.
View Scholar Rock's earnings history
.

How has Scholar Rock's stock price been impacted by COVID-19?

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SRRK stock has increased by 259.0% and is now trading at $53.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SRRK?

5 analysts have issued twelve-month price targets for Scholar Rock's stock. Their forecasts range from $39.00 to $79.00. On average, they anticipate Scholar Rock's share price to reach $61.60 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts' price targets for Scholar Rock
or view top-rated stocks among Wall Street analysts.

Who are Scholar Rock's key executives?

Scholar Rock's management team includes the following people:
  • Mr. Edward H. Myles M.B.A., MBA, CFO & Head of Bus. Operations (Age 49, Pay $55k)
  • Dr. Alan J. Buckler, Chief Scientific Officer (Age 61, Pay $542.61k)
  • Dr. Yung H. Chyung M.D., Chief Medical Officer (Age 45, Pay $564.11k)
  • Mr. Stuart Anthony Kingsley M.B.A., MBA, Pres, CEO & Director (Age 57)
  • Ms. Catherine Hu, VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D., Sr. VP, Head of Legal & Corp. Sec.
  • Dr. Dodzie Sogah Ph.D., Sr. VP of Corp. Devel. & Strategy
  • Ms. Lisa Amaya Price, Sr. VP of HR
  • Dr. Gregory John Carven, Head of Research
  • Ms. Erin Moore, Sr. VP of Fin. (Age 46)

Who are some of Scholar Rock's key competitors?

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.88%), BlackRock Inc. (6.28%), Artal Group S.A. (6.24%), Norges Bank (1.87%), Northern Trust Corp (0.92%) and Morgan Stanley (0.74%). Company insiders that own Scholar Rock stock include Gregory John Carven and Michael Gilman.
View institutional ownership trends for Scholar Rock
.

Which major investors are selling Scholar Rock stock?

SRRK stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Victory Capital Management Inc., JPMorgan Chase & Co., Squarepoint Ops LLC, Nuveen Asset Management LLC, Barclays PLC, Welch & Forbes LLC, and Strs Ohio. Company insiders that have sold Scholar Rock company stock in the last year include Gregory John Carven, and Michael Gilman.
View insider buying and selling activity for Scholar Rock
or view top insider-selling stocks.

Which major investors are buying Scholar Rock stock?

SRRK stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Norges Bank, BlackRock Inc., Lord Abbett & CO. LLC, Frazier Management LLC, Morgan Stanley, Ikarian Capital LLC, and Federated Hermes Inc..
View insider buying and selling activity for Scholar Rock
or or view top insider-buying stocks.

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $53.35.

How much money does Scholar Rock make?

Scholar Rock has a market capitalization of $1.79 billion and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does Scholar Rock have?

Scholar Rock employs 93 workers across the globe.

What is Scholar Rock's official website?

The official website for Scholar Rock is www.scholarrock.com.

Where are Scholar Rock's headquarters?

Scholar Rock is headquartered at 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.